Skip to main content
Fig. 4 | BMC Medical Genomics

Fig. 4

From: Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells

Fig. 4

CXCL2 is involved in anlotinib resistance in NCI-H1975 cells. a, b CXCL2 (50 ng/ml) and anlotinib (4 μg/ml) were performed on NCI-H1975 cells, alone or together for 24 h. Migration rate was examined by wound healing scratch assay. Bars = mean ± SD, n = 3, *P < 0.05, **P < 0.01. Scale bar, 100 μm c, d CXCL2 (100 ng/ml) and anlotinib (2 μg/ml) were performed on NCI-H1975 cells, alone or together, for 24 h. Invasion rate was analyzed based on transwell assays. Bars = mean ± SD, n = 3, **P < 0.01, ***P < 0.001. Scale bar, 100 μm (E, F) NCI-H1975 cells were exposed to CXCL2 (100 ng/ml) and anlotinib (4 μg/ml), alone or together for 24 h. Ratio of total apoptosis and early apoptosis were examined based on flow cytometric detection. Data are shown as mean ± SD, n = 3, *P < 0.05, **P < 0.01, ***P < 0.001

Back to article page
\